[go: up one dir, main page]

LV12290A - Holinoline derivatives with leukotriene antagonist ipasibam - Google Patents

Holinoline derivatives with leukotriene antagonist ipasibam

Info

Publication number
LV12290A
LV12290A LV990068A LV990068A LV12290A LV 12290 A LV12290 A LV 12290A LV 990068 A LV990068 A LV 990068A LV 990068 A LV990068 A LV 990068A LV 12290 A LV12290 A LV 12290A
Authority
LV
Latvia
Prior art keywords
leukotriene antagonist
ipasibam
holinoline
derivatives
well
Prior art date
Application number
LV990068A
Other languages
Latvian (lv)
Other versions
LV12290B (en
Inventor
Robert Zamboni
Daniel Guay
Marc Labelle
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of LV12290A publication Critical patent/LV12290A/en
Publication of LV12290B publication Critical patent/LV12290B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Invention pertains to fluoro containing hydroxyalkylcarbonic acids from the range of quinolines which exhibit leukotriene antagonist properties. Further invention relates to the methods of producing thereof, pharmaceutical compositions containing them and their use. These compounds are useful for treating asthma, allergy and inflammation as well as a cytoprotective agents. They can be used as treating agents of ischaemia, spasms of cerebral blood vessels, glomerulonephritis, hepatitis, endotoxemia and uveitis as well as for preventing rejection of graft tissues.
LVP-99-68A 1992-04-10 1999-04-26 Quinoline derivatives as leukotriene antagonists LV12290B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/866,690 US5270324A (en) 1992-04-10 1992-04-10 Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
CN92105948A CN1080169A (en) 1992-04-10 1992-06-16 Controlled-release tablets containing water-soluble drugs

Publications (2)

Publication Number Publication Date
LV12290A true LV12290A (en) 1999-06-20
LV12290B LV12290B (en) 1999-11-20

Family

ID=25742768

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-68A LV12290B (en) 1992-04-10 1999-04-26 Quinoline derivatives as leukotriene antagonists

Country Status (21)

Country Link
US (1) US5270324A (en)
EP (1) EP0565185B1 (en)
JP (1) JP2504687B2 (en)
CN (2) CN1080169A (en)
AT (1) ATE168100T1 (en)
AU (1) AU653476B2 (en)
BG (1) BG62402B1 (en)
CA (1) CA2092896C (en)
CZ (1) CZ246394A3 (en)
DE (1) DE69319482T2 (en)
ES (1) ES2117691T3 (en)
FI (1) FI944734A7 (en)
HR (1) HRP930803A2 (en)
HU (1) HU218917B (en)
IL (1) IL105193A0 (en)
LV (1) LV12290B (en)
MX (1) MX9302033A (en)
NO (1) NO943792L (en)
SI (1) SI9300188A (en)
WO (1) WO1993021159A1 (en)
ZA (1) ZA932533B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
GB9216768D0 (en) * 1992-08-07 1992-09-23 Leo Pharm Prod Ltd Chemical compounds
ES2080656B1 (en) * 1993-07-19 1996-10-16 Merck Frosst Canada Inc FLUORATED HYDROXYALKYLKINOLINE ACIDS AS LEUCOTRENE ANTAGONISTS.
CA2130723C (en) * 1993-09-03 2006-01-31 Wilhelm Quittmann Process for preparing y-mercaptocarboxylic acid derivatives
DE4339724C1 (en) * 1993-11-22 1995-01-19 Siemens Ag Gas fitting
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
US5491077A (en) * 1994-07-20 1996-02-13 Merck & Co., Inc. Microbial method
US5427933A (en) * 1994-07-20 1995-06-27 Merck & Co., Inc. Reduction of phenylalkyl ketones to the corresponding (S)-hydroxy derivatives using mucor hiemalis IFO 5834
GB9415997D0 (en) * 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
US5545758A (en) * 1994-08-11 1996-08-13 Merck & Co., Inc. Process for the preparation of diisopinocampheylchloroborane
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5648448A (en) * 1995-06-06 1997-07-15 Hitachi Chemical Company, Ltd. Method of preparation of polyquinolines
US5750539A (en) * 1995-06-07 1998-05-12 Merck Frosst Canada Heteroaryl diol acids as leukotriene antagonists
CA2245162A1 (en) * 1996-02-08 1997-08-14 Merck & Co., Inc. Method of treatment and pharmaceutical composition
SK286103B6 (en) * 1997-12-23 2008-03-05 Schering Corporation Pharmaceutical composition for treating respiratory and skin diseases, comprising at least on leucotriene antagonist and at least one antihistamine, and the use of the same
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6696466B1 (en) 2000-09-07 2004-02-24 Leslie Joe Dunaway Methods of treating select neuronal inflammatory disorders using hydroxyalkylquinolines
CA2371048C (en) 2002-02-06 2011-01-04 Delmar Chemicals Inc. Process for the preparation of 1-(mercaptomethyl)-cyclopropaneacetic acid
DE50307710D1 (en) * 2003-08-15 2007-08-30 Abb Turbo Systems Ag rotary seal
AU2004283832B2 (en) * 2003-10-10 2011-04-07 Synthon B.V. Solid-state montelukast
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US20060030550A1 (en) * 2004-08-04 2006-02-09 Lithgow Theodore L Pharmaceutical formulations
WO2006047427A1 (en) 2004-10-25 2006-05-04 Schering Corporation M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
CA2625285A1 (en) * 2005-11-16 2007-05-24 Teva Pharmaceutical Industries Ltd. Drying methods of montelukast sodium by azeotropic removal of the solvent
AR057909A1 (en) * 2005-11-18 2007-12-26 Synthon Bv PROCESS TO PREPARE MONTELUKAST AND RELATED COMPOUNDS, USING AN INTERMEDIATE COMPOUND DERIVED FROM A SULFONIC ESTER.
WO2007107297A1 (en) * 2006-03-17 2007-09-27 Synthon B.V. Montelukast amantadine salt
US20090326232A1 (en) * 2006-06-26 2009-12-31 Uttam Kumar Ray Process for the Preparation of Leukotriene Receptor Antagonist (Montelukast Sodium)
BRPI0712915A2 (en) * 2006-07-11 2012-10-09 Schering Corp xinafoate salt of a substituted 5-oxazal-2-yl-quinoline compound
US7271268B1 (en) 2006-12-22 2007-09-18 Formosa Laboratories Inc. Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
PL205444B1 (en) * 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn The manner of production of salt of 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-ethenylo)phenylo)-3-(2-(1-hydroxy-1- methyloethylo)phenylo)propylo)sulphanylo)methylo)-cyclopropaiacetic acid
EP2265586A4 (en) * 2008-03-17 2012-10-03 Reddys Lab Ltd Dr Preparation of montelukast and its salts
CN102046602A (en) * 2008-04-25 2011-05-04 斯索恩有限公司 Method for preparing montelukast intermediate
AU2010260177A1 (en) 2009-06-16 2011-12-15 Merck Sharp & Dohme Corp. Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
CN103842344B (en) * 2011-07-26 2016-08-03 太阳医药高级研究有限公司 Based on quinoline, quinoxaline or the cysteinyl leukotriene antagonist of benzo [c] thiazole
CN104069502B (en) * 2013-03-29 2018-02-16 北京罗诺强施医药技术研发中心有限公司 Compound skeleton material and its pharmaceutical composition
CN105085391B (en) * 2015-06-10 2017-08-22 广东默泰同创医药科技有限公司 Cyclopropyl unsaturated quionoline compound and application as LTRA

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962203A (en) * 1985-06-18 1990-10-09 Merck Frost Canada, Inc. 2-substituted quinolines useful as leukotriene antagonists
EP0206751A3 (en) * 1985-06-18 1988-05-25 Merck Frosst Canada Inc. 2-substituted quinolines, their preparation and use
US4851409A (en) * 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
EP0271287A3 (en) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Quinoline dioic acids and amides
FR2617352B1 (en) * 1987-06-26 1989-12-01 Eduvision Sa METHOD FOR ENCODING COMPUTER DATA FOR TRANSMISSION TO VIDEO STANDARDS, VIDEODISC IMPLEMENTING SAID METHOD AND INTERFACE FOR OPERATING SUCH A VIDEODISK
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
IL88433A0 (en) * 1987-11-25 1989-06-30 Merck Frosst Canada Inc Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
DE3814504A1 (en) * 1988-04-29 1989-11-09 Bayer Ag (ALPHA) -SUBSTITUTED 4- (CHINOLIN-2-YL-METHOXY) PHENYL ACETIC ACIDS AND SITES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICAMENTS
DE3900261A1 (en) * 1988-05-31 1989-12-07 Bayer Ag SUBSTITUTED 4- (CHINOLIN-2-YL-METHOXY) PHENYL-ACETIC ACID DERIVATIVES
US4918081A (en) * 1988-06-20 1990-04-17 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene d4
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof
DK0480717T3 (en) * 1990-10-12 1999-02-08 Merck Frosst Canada Inc Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists

Also Published As

Publication number Publication date
LV12290B (en) 1999-11-20
BG99085A (en) 1995-06-30
HU218917B (en) 2000-12-28
EP0565185B1 (en) 1998-07-08
ES2117691T3 (en) 1998-08-16
NO943792D0 (en) 1994-10-07
CN1043761C (en) 1999-06-23
DE69319482D1 (en) 1998-08-13
SI9300188A (en) 1993-12-31
FI944734A0 (en) 1994-10-07
FI944734L (en) 1994-10-07
AU3686393A (en) 1993-10-14
NO943792L (en) 1994-12-08
WO1993021159A1 (en) 1993-10-28
CN1080169A (en) 1994-01-05
AU653476B2 (en) 1994-09-29
CN1083052A (en) 1994-03-02
BG62402B1 (en) 1999-10-29
FI944734A7 (en) 1994-10-07
IL105193A0 (en) 1993-07-08
JP2504687B2 (en) 1996-06-05
ATE168100T1 (en) 1998-07-15
CZ246394A3 (en) 1996-01-17
MX9302033A (en) 1994-07-29
EP0565185A1 (en) 1993-10-13
CA2092896A1 (en) 1993-10-11
HUT70399A (en) 1995-10-30
JPH0625173A (en) 1994-02-01
CA2092896C (en) 2005-12-20
US5270324A (en) 1993-12-14
HU9402905D0 (en) 1995-01-30
DE69319482T2 (en) 1999-02-04
ZA932533B (en) 1993-11-04
HRP930803A2 (en) 1994-12-31

Similar Documents

Publication Publication Date Title
LV12290A (en) Holinoline derivatives with leukotriene antagonist ipasibam
FI913478A0 (en) DIAZINDERIVAT.
DE60322267D1 (en) CHINOLINE DERIVATIVES AS GLUCCOKINASE LIGANDS
ATE195315T1 (en) INDOLOCARBAZOLE IMIDES AND THEIR USE
ATE246190T1 (en) HETEROCYCLIC COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE IN THE TREATMENT OF DIABETIS AND RELATED DISEASES
ATE208379T1 (en) 1-PHENYLPYROZOLE COMPOUNDS AND THEIR MEDICAL USES
EP0462813A3 (en) Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase
NO902301D0 (en) PROCEDURE FOR THE PREPARATION OF DIARYLSTYRYLQINOLINE DISYRES.
EP0532705A4 (en) Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene d 4?
RU95111308A (en) Derivatives of 2-amino-4-phenyl-4-oxobutyric acid, methods of synthesis, pharmaceutical composition
EP0434057A3 (en) Indolocarbazole derivatives, processes for their preparation and their use
ATE313539T1 (en) QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS
AU1719392A (en) Leukotriene b4 antagonist
GR3006780T3 (en)
NZ228722A (en) Substituted indole and indazole derivatives and pharmaceutical compositions
MY103259A (en) Aliphatic carboxamides
DE60003031D1 (en) BENZO [F] NAPHTHYRIDINE DERIVATIVES, THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
DE69916103D1 (en) 3-ALKOXYLBENZYLAMINE DERIVATIVES AND THEIR USE AS A MEDICAMENT FOR THE TREATMENT OF SCHIZOPHRENIA
TH40569A (en) Quino Saline Dione
TH64140A (en) Benzodiazepines [g] quinoline for the treatment of glaucoma and myopia.